USO 24139
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GCT1184-02)
Disease Types: GYN Cancer Research
Eligibility Requirements:
• Histologically or cytologically confirmed high grade serous or
endometrioid epithelial OC/FP/PPC
• 1 to 4 prior lines of therapy, must include:
• Platinum chemotherapy
• Prior bevacizumab
• PARP inhibitor as maint for pts w/ germline BRCA mutations and who
achieved CR/PR to plt-based chemo
• Mirvetuximab soravtansine if indicated
• Pt must have platinum-resistant disease
• FRα expression result per Ventana FOLR1-2.1 RxDx Assay must
be available prior to randomization
• Measurable disease per RECIST v1.1
• No prior tx with ADC containing topoisomerase I inhibitor
For more information on this trial CLICK HERE .
Available at: